- Home
- MOLN vs TEAF Comparison
MOLN vs TEAF Comparison
Compare MOLN & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- TEAF
- Stock Information
- Founded
- MOLN 2004
- TEAF 2017
- Country
- MOLN Switzerland
- TEAF United States
- Employees
- MOLN N/A
- TEAF N/A
- Industry
- MOLN
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- MOLN
- TEAF Finance
- Exchange
- MOLN Nasdaq
- TEAF Nasdaq
- Market Cap
- MOLN 192.4M
- TEAF 174.8M
- IPO Year
- MOLN 2021
- TEAF N/A
- Fundamental
- Price
- MOLN $4.89
- TEAF $12.24
- Analyst Decision
- MOLN
- TEAF
- Analyst Count
- MOLN 0
- TEAF 0
- Target Price
- MOLN N/A
- TEAF N/A
- AVG Volume (30 Days)
- MOLN 5.7K
- TEAF 56.1K
- Earning Date
- MOLN 03-13-2025
- TEAF 01-01-0001
- Dividend Yield
- MOLN N/A
- TEAF 9.20%
- EPS Growth
- MOLN N/A
- TEAF N/A
- EPS
- MOLN N/A
- TEAF N/A
- Revenue
- MOLN $7,105,397.00
- TEAF N/A
- Revenue This Year
- MOLN N/A
- TEAF N/A
- Revenue Next Year
- MOLN $29.41
- TEAF N/A
- P/E Ratio
- MOLN N/A
- TEAF N/A
- Revenue Growth
- MOLN N/A
- TEAF N/A
- 52 Week Low
- MOLN $3.32
- TEAF $11.11
- 52 Week High
- MOLN $12.70
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- MOLN 41.97
- TEAF 51.19
- Support Level
- MOLN $5.22
- TEAF $12.03
- Resistance Level
- MOLN $5.35
- TEAF $12.20
- Average True Range (ATR)
- MOLN 0.12
- TEAF 0.13
- MACD
- MOLN -0.03
- TEAF 0.01
- Stochastic Oscillator
- MOLN 0.00
- TEAF 37.78
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.